Shern L. Chew - Concepedia

Author

Shern L. Chew

St Bartholomew's Hospital

Also Known As

Chew, Shern L., D Tolpin, S CHEW, S L Chew, S. Chew, S. L. CHEW, S. L. Chew, S.L Chew, S.L. Chew, Shern Chew

139

Publications

8.3K

Citations

H-Index

118

Concepts

All Affiliations

St Bartholomew's Hospital Queen Mary University of London Cold Spring Harbor Laboratory University of Birmingham Barts Health NHS Trust

About

Shern L. Chew is an author at St Bartholomew's Hospital specializing in medicine, pathology, and adrenal disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	30	2.3K
2	Health Sciences	3	3	96
3	Natural Sciences	2	2	146
4	Engineering	1	1	102
5	Public Health	1	1	32

Shern L. Chew

Publications

Citations

H-Index

Page 1

	Year	Citations
An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers Philip J Smith, Chaolin Zhang, Jinhua Wang, Human Molecular Genetics	2006	499
Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. Simon H. S. Pearce, Dorothy Trump, C Wooding, Journal of Clinical Investigation Car GeneDevelopmental BiologyNeonatal HyperparathyroidismMendelian DisorderGenetic Disorder	1995	349
Tumor risks and genotypeâphenotypeâproteotype analysis in 358 patients with germline mutations in<i>SDHB</i>and<i>SDHD</i> Christopher J. Ricketts, Julia Forman, Eleanor Rattenberry, Human Mutation	2009	336
Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. József Szabó, Bobby Heath, Virginia Hill, PubMed	1995	254
Exonic Splicing Enhancer Motif Recognized by Human SC35 under Splicing Conditions Hongxiang Liu, Shern L. Chew, Luca Cartegni, Molecular and Cellular Biology	2000	243
A Short Isoform of the Human Growth Hormone Receptor Functions as a Dominant Negative Inhibitor of the Full-Length Receptor and Generates Large Amounts of Binding Protein Richard Ross, Nazario Esposito, Xiongjie Shen, Molecular Endocrinology	1997	216
Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study Krystallenia Alexandraki, Gregory Kaltsas, Andrea M. Isidori, European Journal of Endocrinology	2013	204
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. Charis Eng, Paul A. Crossey, Lois M. Mulligan, Journal of Medical Genetics GeneticsPathologyMolecular GeneticsRet Proto-oncogeneSporadic Tumours	1995	172
Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with <sup>131</sup>I‐meta‐iodobenzylguanidine (<sup>131</sup>I‐mIBG) Jagat J. Mukherjee, Gregory Kaltsas, Najmul Islam, Clinical Endocrinology	2001	165
Discriminatory Value of the Low-Dose Dexamethasone Suppression Test in Establishing the Diagnosis and Differential Diagnosis of Cushing’s Syndrome Andrea M. Isidori, Gregory Kaltsas, Shahid Mohammed, The Journal of Clinical Endocrinology & Metabolism Cushing ’Adrenal GlandPituitary GlandHigh SensitivityDifferential Diagnosis	2003	155

Page 1